Research  >  About SRI  >  Scientist Profiles

Scientist profiles G-L

SRI Profiles

Andrew Loblaw, MD, FRCPC, M.Sc.


Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room T2 243
Toronto, ON
M4N 3M5

Phone: 416-480-4806
Fax: 416-480-6002

Executive Assistant: Barb Zurowski
Phone: 416-480-4806

Clinical ProfileShow/hide details

Andrew Loblaw is a radiation oncologist, clinician scientist and an associate professor in the departments of radiation oncology and health policy management and evaluation at the University of Toronto. He has a masters in clinical epidemiology from the University of Toronto and is a graduate of the Royal College's Clinician Investigator Program. His clinical practice focuses on prostate cancer.

Appointments and affiliations:
  • Active staff, radiation oncology, Sunnybrook
  • Courtesy staff, surgery, North York General Hospital
Clinical focus: prostate cancer

Research Profile
Show/hide details


  • B.Sc., 1991, physics, University of British Columbia
  • MD, 1995, Queen’s University
  • FRCPC, 2000, radiation oncology, University of Toronto
  • M.Sc., 2002, clinical epidemiology, U of T
  • FRCPC, 2002, clinician investigator program, U of T

Appointments and affiliations:

  • Scientist, Evaluative Clinical SciencesOdette Cancer Research Program, Sunnybrook Research Institute
  • Clinician scientist, Ontario Association of Radiation Oncology
  • Associate professor, department of radiation oncology, U of T
  • Associate professor, Institute of Health Policy, Management and Evaluation, U of T
  • North American editor, Clinical Oncology
  • Co-chair, Genitourinary Cancer Disease Site Group, Cancer Care Ontario
  • Co-chair, Genitourinary Guidelines Advisory Group, American Society of Clinical Oncology

Research focus:

Improving outcomes for men with prostate cancer through evidence-based guidelines, novel radiotherapeutic strategies, active surveillance and lifestyle modifications.

Research summary:

Dr. Loblaw has enhanced evidence-based medicine significantly in two areas, and has developed a national medical career guidance program.

Evidence-based and clinical practice guidelines are the foundation of evidence-based medicine. Dr. Loblaw has led the production of four documents on this topic, all of which have been published in international peer-reviewed journals and have led to setting and changing practice standards worldwide. His work has been widely cited in top-named journals, and he has been invited to speak and join committees nationally and internationally. He has also taken the lead on new research questions arising from the work to strengthen further the evidence addressing these topics.

Career selection is stressful for medical students. Dr. Loblaw was instrumental in developing the only nationally recognized and distributed medical career guidance program. The foundation of this work is a book that is in its fourth edition and is available in French and English. The book, distributed in every medical school in Canada, is the standard reference for medical students as they pursue specialty training positions. Because of his contributions to this career guidance program, Dr. Loblaw has received invitations to speak at various medical schools and to student groups, and has helped set up a national speaking series to address these students' needs.

Selected publications:

See current publications list at PubMed.

  1. Loblaw DA, Walker-Dilks C, Winquist E, Hotte S and Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol. 2013 Jul;25(7):406–30.
  2. Loblaw DA, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L, Tang C, Quon H, Jain S, Pang G, Nam RK. Prostate stereotactic body radiotherapy using a standard linear accelerator: toxicity, biochemical and pathological outcomes. Radiother Oncol. 2013 May;107(2):153–8.
  3. Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK, Lyman GH and Basch E. American Society of Clinical Oncology clinical practice guidelines: formal systematic review-based consensus methodology. J Clin Oncol. 2012 Sep;30(25):3136–40.
  4. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran P, Tirona R, Cardoso M, Pang G, Gardner S. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy for low-risk localized prostate cancer: early results of pHART3. Clin Oncol. 2008 Dec;20(10):729–37.
  5. Loblaw DA, Virgo KS, Nam R, Somerfield M, Ben-Josef E, Mendelson DS, Middleton R, Porterfield H, Sharp SA, Talcott J, Taplin ME, Vogelzang NJ, Wade JL, Bennett CL, Scher HI. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr;25(12): 1596–1605.

Related News and Stories:

Related Links: